I-Mab (NASDAQ:IMAB – Get Free Report) will announce its earnings results before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
I-Mab (NASDAQ:IMAB – Get Free Report) last issued its quarterly earnings results on Wednesday, August 28th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.44. On average, analysts expect I-Mab to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
I-Mab Stock Performance
NASDAQ IMAB opened at $1.10 on Tuesday. The company’s 50 day simple moving average is $1.19 and its 200 day simple moving average is $1.43. I-Mab has a 12 month low of $0.99 and a 12 month high of $2.54.
Analysts Set New Price Targets
Get Our Latest Report on I-Mab
About I-Mab
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
Read More
- Five stocks we like better than I-Mab
- What Are Dividend Achievers? An Introduction
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Short Selling: How to Short a Stock
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.